|
JP2023530319A
(ja)
|
2020-06-17 |
2023-07-14 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Ｎａｖ１．８阻害剤としての２－オキソ－オキサゾリジン－５－カルボキサミド
|
|
MX2023013147A
(es)
*
|
2021-05-07 |
2023-11-28 |
Merck Sharp & Dohme Llc |
Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
|
|
EP4334293A1
(en)
*
|
2021-05-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
|
|
WO2022256676A1
(en)
|
2021-06-04 |
2022-12-08 |
Vertex Pharmaceuticals Incorporated |
Substituted tetrahydrofuran analogs as modulators of sodium channels
|
|
MA64856B1
(fr)
|
2021-06-04 |
2026-02-27 |
Vertex Pharmaceuticals Incorporated |
Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide
|
|
SI4347031T1
(sl)
|
2021-06-04 |
2026-01-30 |
Vertex Pharmaceuticals Incorporated |
N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
|
|
CA3221788A1
(en)
|
2021-06-04 |
2022-12-08 |
Vertex Pharmaceuticals Incorporated |
Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
|
|
JP2024520646A
(ja)
|
2021-06-04 |
2024-05-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体
|
|
JP2024520643A
(ja)
|
2021-06-04 |
2024-05-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン
|
|
AU2023257313A1
(en)
|
2022-04-22 |
2024-10-31 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds for the treatment of pain
|
|
UY40234A
(es)
|
2022-04-22 |
2023-11-15 |
Vertex Pharma |
Compuestos heteroarilo para el tratamiento del dolor
|
|
GEAP202516634A
(en)
|
2022-04-22 |
2025-02-25 |
Vertex Pharma |
Heteroaryl compounds for the treatment of pain
|
|
JP2025513452A
(ja)
|
2022-04-22 |
2025-04-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
疼痛の治療のためのヘテロアリール化合物
|
|
IL316433A
(en)
|
2022-04-25 |
2024-12-01 |
Siteone Therapeutics Inc |
Bicyclic heterocyclic amide inhibitors of NA v1.8 for the treatment of pain
|
|
AU2023391870A1
(en)
|
2022-12-06 |
2025-06-05 |
Vertex Pharmaceuticals Incorporated |
Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
|
|
WO2025090516A1
(en)
|
2023-10-23 |
2025-05-01 |
Vertex Pharmaceuticals Incorporated |
Methods of preparing compounds for treating pain and solid forms thereof
|
|
WO2025090480A1
(en)
|
2023-10-23 |
2025-05-01 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds for the treatment of pain
|
|
WO2025090465A1
(en)
|
2023-10-23 |
2025-05-01 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds for the treatment of pain
|
|
WO2025090511A1
(en)
|
2023-10-23 |
2025-05-01 |
Vertex Pharmaceuticals Incorporated |
Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
|
|
WO2025122953A1
(en)
|
2023-12-07 |
2025-06-12 |
Vertex Pharmaceuticals Incorporated |
Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
|
|
WO2025160286A1
(en)
|
2024-01-24 |
2025-07-31 |
Siteone Therapeutics, Inc. |
2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
|
|
US20260001877A1
(en)
|
2024-06-28 |
2026-01-01 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds for the treatment of pain
|
|
WO2026013449A2
(en)
|
2024-07-11 |
2026-01-15 |
Sea4Us - Biotecnologia E Recursos Marinhos, Sa |
Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
|
|
WO2026030525A1
(en)
|
2024-07-31 |
2026-02-05 |
Vertex Pharmaceuticals Incorporated |
Zilvetrigine dosage forms and dosing regimens for treating pain
|